Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
24 Results for "
TGF-βRI
" in MedChemExpress (MCE) Product Catalog:
Products (24)
24 Results for "TGF-βRI" in MCE Product Catalog:
72
72 Publications Verification
Synonyms: LY2157299
Target:
Research Areas:
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
24
Target:
Research Areas:
LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM, and exhibits 7-fold selectivity over TGFβR-II .
19
19 Cited Publications
Cat. No.: HY-N0439
CAS No.: 16830-15-2
10
10 Cited Publications
Target:
Research Areas:
SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, and > 100-fold selectivity over TGF-βRII.
1
1 Cited Publications
Cat. No.: HY-P78525
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: TGFBR1; Serine/Threonine-Protein Kinase Receptor R4; Prev. ESS1; Activin Receptor-Like Kinase 5; Prev. MSSE; TbetaR-I; ALK-5; TGFR-1; ALK5; SKR4; Transforming Growth Factor-Beta Receptor Type I; Multiple Self-Healing Squamous Epithelioma; TGF-Beta Recepto
Cat. No.: HY-N0439R
CAS No.: 16830-15-2
Cat. No.: HY-137918
CAS No.: 666729-57-3
Research Areas:
TGF-βRI inhibitor 3 (Compound 9ac) is a selective TGF-β inhibitor. TGF-βRI inhibitor 3 can effectively inhibit the TGF-β signaling pathway. TGF-βRI inhibitor 3 has IC50 values of 13 μM and 0.63 μM for c-Src kinase and ALK5 kinase, respectively .
Target:
Research Areas:
ALK5-IN-8 is a potent inhibitor of TGFβRI (ALK5). ALK5-IN-8 Inhibits the phosphorylation of ALK5 on its downstream signaling proteins (Smad2 or Smad3) by blocking the binding of TGFβRI to ligands, thereby affecting or blocking TGF-β signaling. ALK5-IN-8 has the potential for the research of various ALK5-mediated related diseases (extracted from patent WO2021190425A1, compound 1) .
Target:
Research Areas:
TGFβRI-IN-3 inhibits TGFβR1 at an IC50 of 0.79 nM with 2000-fold selectivity against MAP4K4. TGFβRI-IN-3 represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology .
Target:
Research Areas:
TP-008, a chemical probe, is a potent, selective and orally active (Activin-Like Kinase 5) ALK5 inhibitor with pIC50 and pEC50 values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose .
Cat. No.: HY-171878
CAS No.: 894784-05-5
Target:
Research Areas:
BI-4659 is a TGFβRI and PDGFRα inhibitor with IC50 values of 19 nM and 99 nM, respectively. BI-4659 inhibits the kinase activities of TGFβRI and PDGFRα, blocks the downstream TGFβRI signaling pathway, and reduces the phosphorylation level of Smad2/3 without altering the expression of TGF-β1. BI-4659 is applicable to research related to pulmonary fibrosis, cancer, and renal ischemia-reperfusion injury .
Cat. No.: HY-W028145
CAS No.: 476474-11-0
Target:
Research Areas:
TGF-βRI inhibitor 2 (compound 13) is a TGF-βRI inhibitor. TGF-βRI inhibitor 2 can be used in cancer research .
Cat. No.: HY-112864
CAS No.: 2072051-04-6
Target:
Research Areas:
TGFβRI-IN-6 (compound 22) is a potent TGFβRI inhibitor with an IC50 value of 0.55 nM. TGFβRI-IN-6 has the potential to enhance anti-tumor immunity .
Cat. No.: HY-178231
CAS No.: 2766583-86-0
Synonyms: ALK5-IN-85
Target:
Research Areas:
Finbosertib (ALK5-IN-85) (Compound 19) is a TGFβRI (ALK5) inhibitor with an IC50 of <100 nM. Finbosertib can be used for respiratory diseases including idiopathic pulmonary fibrosis, asthma, COPD and lumg cancer, and dermal and ocular fibrotic conditions research .
Cat. No.: HY-13226A
CAS No.: 924898-09-9
Target:
Research Areas:
Galunisertib monohydrate is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
Cat. No.: HY-13226R
CAS No.: 700874-72-2
Synonyms: LY2157299 (Standard)
Target:
Research Areas:
Galunisertib (Standard) is the analytical standard of Galunisertib. This product is intended for research and analytical applications. Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
Cat. No.: HY-144437
CAS No.: 2489611-06-3
Target:
Research Areas:
ALK5-IN-9 (Compound 8h) is a potent and orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation and NIH3T3 cell activity with IC50 values of 25 nM and 74.6 nM, respectively. ALK5-IN-9 also shows favorable pharmacokinetic profile and ameliorated hERG inhibition. ALK5-IN-9 has the potential for the research of cancer disease .
Cat. No.: HY-114192
CAS No.: 1950628-94-0
Target:
Research Areas:
TGFβRI-IN-1 is an oral active and selective TGFβ receptor type I (TGFβRI) kinase inhibitor, with IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively .
Cat. No.: HY-172108
Target:
Research Areas:
TGFβRI-IN-7 (compound 16W) is a potent inhibitor of TGFβRI. TGFβRI-IN-7 inhibits SMAD2/3 phosphorylation and H22 cell viability with IC50 values of 12 and 65 nM, respectively. TGFβRI-IN-7 shows anti-tumor efficacy in a xenograft model of H22 cells, with TGI of 79.6 % .
Cat. No.: HY-147786
CAS No.: 2541690-15-5
Target:
Research Areas:
TGFβRI-IN-5 (Compound 4b) is a potent inhibitor of TGFβRI with an IC50 of 0.08 μM. TGFβRI-IN-5 displays amazing anticancer activity 5–7 times that of reference agent against all the tested cell lines. TGFβRI-IN-5 enhances apoptosis and arrested G2/M phase of cell cycle .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
